Consistent with the results above, the pan-caspase inhibitor ZVAD-FMK substantially reduced the level of bortezomib-induced C-terminal MLKL fragment in MLKLWT-Flag expressing MM cells (Figure 4E (lanes 1-3) and S8B). Here, MLKL is linked to Miyoshi myopathy.